335 related articles for article (PubMed ID: 32575406)
1. Injectable Lipid-Based Depot Formulations: Where Do We Stand?
Rahnfeld L; Luciani P
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32575406
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in lipid-based long-acting injectable depot formulations.
Sharma R; Yadav S; Yadav V; Akhtar J; Katari O; Kuche K; Jain S
Adv Drug Deliv Rev; 2023 Aug; 199():114901. PubMed ID: 37257756
[TBL] [Abstract][Full Text] [Related]
4. Advances in lipid nanodispersions for parenteral drug delivery and targeting.
Constantinides PP; Chaubal MV; Shorr R
Adv Drug Deliv Rev; 2008 Mar; 60(6):757-67. PubMed ID: 18096269
[TBL] [Abstract][Full Text] [Related]
5. Rationale utilization of phospholipid excipients: a distinctive tool for progressing state of the art in research of emerging drug carriers.
Jebastin K; Narayanasamy D
J Liposome Res; 2023 Mar; 33(1):1-33. PubMed ID: 35543241
[TBL] [Abstract][Full Text] [Related]
6. Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes.
d'Aquino AI; Maikawa CL; Nguyen LT; Lu K; Hall IA; Jons CK; Kasse CM; Yan J; Prossnitz AN; Chang E; Baker SW; Hovgaard L; Steensgaard DB; Andersen HB; Simonsen L; Appel EA
bioRxiv; 2023 Jul; ():. PubMed ID: 36778223
[TBL] [Abstract][Full Text] [Related]
7. Vesicular phospholipid gels as drug delivery systems for small molecular weight drugs, peptides and proteins: State of the art review.
Breitsamer M; Winter G
Int J Pharm; 2019 Feb; 557():1-8. PubMed ID: 30572079
[TBL] [Abstract][Full Text] [Related]
8. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
[TBL] [Abstract][Full Text] [Related]
9. Study on the in situ aggregation of liposomes with negatively charged phospholipids for use as injectable depot formulation.
Rahnfeld L; Thamm J; Steiniger F; van Hoogevest P; Luciani P
Colloids Surf B Biointerfaces; 2018 Aug; 168():10-17. PubMed ID: 29478769
[TBL] [Abstract][Full Text] [Related]
10. In Situ Forming Depot as Sustained-Release Drug Delivery Systems.
Kanwar N; Sinha VR
Crit Rev Ther Drug Carrier Syst; 2019; 36(2):93-136. PubMed ID: 30806210
[TBL] [Abstract][Full Text] [Related]
11. Clinically established biodegradable long acting injectables: An industry perspective.
Nkanga CI; Fisch A; Rad-Malekshahi M; Romic MD; Kittel B; Ullrich T; Wang J; Krause RWM; Adler S; Lammers T; Hennink WE; Ramazani F
Adv Drug Deliv Rev; 2020 Dec; 167():19-46. PubMed ID: 33202261
[TBL] [Abstract][Full Text] [Related]
12. An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems.
Janagam DR; Wang L; Ananthula S; Johnson JR; Lowe TL
Pharmaceutics; 2016 Sep; 8(3):. PubMed ID: 27598191
[TBL] [Abstract][Full Text] [Related]
13. Long-Acting Injectables: Current Perspectives and Future Promise.
Chaudhary K; Patel MM; Mehta PJ
Crit Rev Ther Drug Carrier Syst; 2019; 36(2):137-181. PubMed ID: 30806211
[TBL] [Abstract][Full Text] [Related]
14. Poly(ethylene glycol)-
Cagnon ME; Curia S; Serindoux J; Cros JM; Ng F; Lopez-Noriega A
Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33922166
[TBL] [Abstract][Full Text] [Related]
15. Biopredictive tools for the development of injectable drug products.
Villa Nova M; Gan K; Wacker MG
Expert Opin Drug Deliv; 2022 Jun; 19(6):671-684. PubMed ID: 35603724
[TBL] [Abstract][Full Text] [Related]
16. Evolution of drug delivery systems: From 1950 to 2020 and beyond.
Park H; Otte A; Park K
J Control Release; 2022 Feb; 342():53-65. PubMed ID: 34971694
[TBL] [Abstract][Full Text] [Related]
17. Injectable
Bisht R; Nirmal S; Agrawal R; Jain GK; Nirmal J
J Drug Target; 2021 Jan; 29(1):46-59. PubMed ID: 32729731
[TBL] [Abstract][Full Text] [Related]
18. Model for Long Acting Injectables (Depot Formulation) Based on Pharmacokinetics and Physical Chemical Properties.
Shah JC; Hong J
AAPS J; 2022 Mar; 24(3):44. PubMed ID: 35298711
[TBL] [Abstract][Full Text] [Related]
19. Prolonged local delivery of doxorubicin to cancer cells using lipid liquid crystalline system.
Karimi M; Kamali H; Fakhrmohammadi S; Khezri E; Malaekeh-Nikouei B; Mohammadi M
Int J Pharm; 2023 May; 639():122947. PubMed ID: 37044227
[TBL] [Abstract][Full Text] [Related]
20. Beyond Q1/Q2: The Impact of Manufacturing Conditions and Test Methods on Drug Release From PLGA-Based Microparticle Depot Formulations.
Garner J; Skidmore S; Park H; Park K; Choi S; Wang Y
J Pharm Sci; 2018 Jan; 107(1):353-361. PubMed ID: 29107048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
